

# Introduction: cardiometabolic considerations in COVID-19

Andrew J. Krentz

Institute for Cardiovascular and Metabolic Research, University of Reading, Reading, UK

Correspondence to Andrew J. Krentz, MD, FRCP, FFPM, Institute for Cardiovascular and Metabolic Research, University of Reading, UK

E-mail: andrew.krentz@reading.ac.uk

Received 25 June 2020 Accepted 25 June 2020

The journal is pleased to present a collection of timely articles that consider issues of relevance both to the current coronavirus disease 2019 (COVID-19) pandemic as it unfolds and to preparedness against future challenges.

While many uncertainties remain and much speculation continues to circulate, early insights into the importance of diabetes, obesity and cardiovascular disease to COVID-19 susceptibility and higher case fatality rates have been borne out by multiple studies. As Dhindsa *et al* [1], point out these cardiometabolic disorders represent a parallel non-communicable global challenge that will continue to present a threat to millions of individuals worldwide after the current coronavirus threat has passed. The full impact of the interruptions to aspects of preventive healthcare, including diabetes and cardiovascular disease, has yet to be quantified.

The journal has sought to fast track COVID-19 articles and they have been made available on the *Cardiovascular Endocrinology & Metabolism* website in the Online First section once accepted.

The reviewers who completed their tasks promptly during this challenging time are thanked for their support of the peer review process.

## Acknowledgements

### Conflicts of interest

There are no conflicts of interest.

## Reference

- 1 Dhindsa DS, Wong ND, Sperling L. Cardiovascular and cardiometabolic prevention: High level priority in the era of COVID-19. *Cardiovasc Endocrinol Metab* 2020,9:125–127.